Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|April 10, 2020
Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 studyMichael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, et al.
British Journal of Haematology|June 26, 2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myelomaPaul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, et al.
Transplantation and Cellular Therapy|January 21, 2023
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution ExperienceTaxiarchis Kourelis, Radhika Bansal, Jesus Berdeja, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2011
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myelomaFiroozeh Sahebi, Paul H Frankel, Len Farol, et al.
Cancer Medicine|April 21, 2023
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experienceIdoroenyi Amanam, Janny Yao, Alfredo Puing, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse SurvivalMyo Htut, Anita D'Souza, Amrita Krishnan, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyAdam D Cohen, Parameswaran Hari, Myo Htut, et al.
Blood|June 3, 2026
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myelomaSusan Bal, Myo Htut, Omar Nadeem, et al.
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Pageof 5